Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome

What Was Tested

This registered not phased trial tested Triptorelin.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

It had 1 arm (groups): Repeated GnRHa (experimental).

Patients were triggered with repeated GnRHa.

The registry classes the interventions as drug.

More on the Plan

This was a prospective cohort study of all women attending the Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, affiliated with Southern Medical University for in vitro fertilization and/or intracytoplasmic sperm injection .

Women at high risk of OHSS who received IVF and/or intracytoplasmic sperm injection (ICSI) treatment with a flexible GnRH antagonist protocol were recruited to participate in this study.

Who Took Part

The registry lists 80 planned participants were the target.

It was open to women only aged up to 40 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients with polycystic ovarian syndrome. Patients with polycystic ovarian morphology on ultrasound. Patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins.

The full record lists 3 inclusion and 2 exclusion criteria; among the exclusions: patients undergoing coasting; patients with past ovarian surgery.

How the Study Was Run

It was run as a non-randomized, single-group and open-label study.

Everyone knew when Triptorelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2012-07 with completion listed for 2015-12.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): clinical pregnancy rate per transfer cycle (time frame: 1month post embryo transfer). numbers of patients having OHSS (time frame: 2 weeks post trigger with repeated GnRHa). oocyte yield (time frame: oocyte retrieval day (34 to 38 hours post the first trigger with GnRHa)).

It also tracked 4 secondary outcomes, for example serum luteinizing hormone level 12 hours post first trigger, serum luteinizing hormone level 24 hours post first trigger, fertilization rate and implantation rate.

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Triptorelin in 80 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Triptorelin compound page, all human trials.